Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mirodenafil

Drug Profile

Mirodenafil

Alternative Names: Aibishi; Bravonto; Mvix; SK-3530

Latest Information Update: 02 Jul 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SK Chemicals
  • Developer In2Gen; SK Chemicals
  • Class Erectile dysfunction therapies; Piperazines; Pyrimidinones; Small molecules; Sulfones
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Erectile dysfunction

Most Recent Events

  • 29 Jan 2015 SK Chemicals completes a phase I pharmacokinetic trial in Renal impaired patients in South Korea (NCT01232010)
  • 05 Apr 2008 Pharmacokinetics data from a Phase-I trial in healthy volunteers presented at the 109th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT-2008)
  • 01 Aug 2007 First global launch of mirodenafil for Erectile dysfunction [South Korea]
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top